CAMBRIDGE, Mass., May 24 /PRNewswire-FirstCall/ -- Javelin Pharmaceuticals, Inc. , today announced that Daniel B. Carr, MD, Chief Executive Officer and Chief Medical Officer, will make an investor presentation at Friedman, Billings, Ramsey's (FBR) 2006 Growth Investor Conference. Nearly 140 growth companies will present to investors, primarily from the technology, media, telecommunications and healthcare sectors.
The FBR 2006 Growth Investor Conference will take place in midtown Manhattan on Wednesday, May 31 and Thursday, June 1, 2006. Dr. Carr's presentation will take place on Thursday, June 1, from 10:30 AM to 11:10 AM in Room 5 at the Grand Hyatt New York Hotel at Grand Central Station.
Dr. Carr's presentation will be webcast live and available for replay at http://www.wsw.com/webcast/fbr15/jvph.ob/ and on Javelin's website at http://www.javelinpharmaceuticals.com.
Friedman, Billings, Ramsey Group, Inc. provides investment banking, institutional brokerage and asset management services. For more information, visit http://www.fbr.com.
About Javelin
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the company's website at http://www.javelinpharmaceuticals.com.
Forward Looking Statement
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
Javelin Pharmaceuticals, Inc.CONTACT: June Gregg of Javelin Pharmaceuticals, Inc., +1-212-554-4550,jgregg@javelinpharmaceuticals.com; or Bryan Murphy of LaVoie Group,+1-781-596-0200 X105, bmurphy@lavoiegroup.com, for Javelin Pharmaceuticals,Inc.
